Clinical and preclinical activity of 2',2'-... [Cancer Treat Rev. 1993] - PubMed

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). [Cancer Res. 1990]
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Cancer Res. 1990 Jul 15; 50(14):4417-22.
Review Gemcitabine: a cytidine analogue active against solid tumors. [Am J Health Syst Pharm. 1997]
Review Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF, Reitz J. Am J Health Syst Pharm. 1997 Jan 15; 54(2):162-70; quiz 197-8.
Review Preclinical, pharmacologic, and phase I studies of gemcitabine. [Semin Oncol. 1997]
Review Preclinical, pharmacologic, and phase I studies of gemcitabine.
Storniolo AM, Allerheiligen SR, Pearce HL. Semin Oncol. 1997 Apr; 24(2 Suppl 7):S7-2-S7-7.
Review Gemcitabine in the treatment of metastatic pancreatic cancer. [Expert Rev Anticancer Ther. 2008]
Review Gemcitabine in the treatment of metastatic pancreatic cancer.
Hilbig A, Oettle H. Expert Rev Anticancer Ther. 2008 Apr; 8(4):511-23.
Gemcitabine: novel combination of efficacy and tolerability. [Anticancer Drugs. 1993]
Gemcitabine: novel combination of efficacy and tolerability.
. Anticancer Drugs. 1993 Dec; 4(6):671.

A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study. [Cancer Res Treat. 2004]
A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.
Park JS, Lee CM, Lee SA, Jung CK, Kim SH, Kwon HC, Kim JS, Kim HJ. Cancer Res Treat. 2004 Feb; 36(1):62-7. Epub 2004 Feb 29.
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. [J Occup Med Toxicol. 2008]
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.
Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. J Occup Med Toxicol. 2008 Dec 18; 3:34. Epub 2008 Dec 18.
Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial. [Br J Cancer. 1999]
Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M, Traine G, Cinat G, Cazap E, Comba AZ, Vicente H, Sena S, Nievas OR, Orlando M. Br J Cancer. 1999 Nov; 81(5):846-9.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).
Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).
Cancer Treat Rev. 1993 Jan ;19(1):45-55.

PubMed
Platelet activating factor (PAF) is a potent stimulator of porcine tracheal flui...
Platelet activating factor (PAF) is a potent stimulator of porcine tracheal fluid secretion in vitro.
Eur J Pharmacol. 1987 Oct 27 ;142(3):367-72.

PubMed
Airway epithelial cell mucin release: immunologic quantitation and response to p...
Airway epithelial cell mucin release: immunologic quantitation and response to platelet-activating factor.
Am J Respir Cell Mol Biol. 1992 Feb ;6(2):158-67.

PubMed
Platelet-activating factor increases leukotriene B4 release in stimulated alveol...
Platelet-activating factor increases leukotriene B4 release in stimulated alveolar macrophages from asthmatic patients.
Eur Respir J. 1998 May ;11(5):1098-104.

PubMed
Urinary N-acetyl-beta-D-glucosaminidase (NAG) isoenzyme profiles: a tool for eva...
Urinary N-acetyl-beta-D-glucosaminidase (NAG) isoenzyme profiles: a tool for evaluating nephrotoxicity of aminoglycosides and cephalosporins.
Clin Chim Acta. 1984 Feb 14 ;137(1):1-11.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed